{"entity":{"id":"dauntless-biotherapeutics","kind":"company","name":"Dauntless Biotherapeutics","aka":["DAUNTLESS BIOTHERAPEUTICS, INC."],"tldr":"Dauntless Biotherapeutics is a San Diego area company developing an antibody that carries a drug to cancer cells, aimed at cancers with few treatment options.","summary":"Dauntless Biotherapeutics, Inc. is a private preclinical oncology company developing an antibody-drug conjugate against an undisclosed tumour-associated antigen; its website says it is raising a seed round for lead optimisation, in vivo and non-GLP toxicity studies before an investigational new drug filing. In fiscal year 2026 the National Cancer Institute funded its SBIR project on a dual-function antibody therapeutic to overcome breast cancer resistance (1R43CA306683-01A1, USD 400,000).","asOf":"2026-11-04","links":[{"label":"Official website","url":"https://www.dauntlessbiotherapeutics.com/"},{"label":"NIH RePORTER: 1R43CA306683-01A1","url":"https://reporter.nih.gov/project-details/11407449"}],"tags":[],"related":[],"cancers":["breast-cancer"],"sections":["adcs"],"technologies":["adc"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["NIH RePORTER gives San Diego; the website gives an address in Carlsbad, California. Read on 4 November 2026. The site names no product."],"hq":"San Diego, CA","country":"US","companyType":"biotech","website":"https://www.dauntlessbiotherapeutics.com/","stage":"startup","investors":[],"funding":[{"round":"Grant","year":2026,"amountUsd":400000,"source":"https://reporter.nih.gov/project-details/11407449","note":"NCI SBIR Phase I (R43) award 1R43CA306683-01A1: Overcoming Breast Cancer Resistance with a Dual-Function Antibody Therapeutic"}]},"route":"/companies/dauntless-biotherapeutics/","neighbours":{"cancer":[{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"}],"section":[{"id":"adcs","kind":"section","name":"Antibody-Drug Conjugates","route":"/fronts/adcs/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"}]}}